Dennis Slamon, TORL BioTherapeutics co-founder (UCLA Health)
April 14, 2023 01:53 PM EDTUpdated 02:30 PM
Financing
Startups

Her­ceptin founder snags $158M for his UCLA-biotech part­ner­ship TORL Bio­Ther­a­peu­tics

Kyle LaHucik

Senior Reporter

One of the key re­searchers be­hind iden­ti­fy­ing HER2 as a breast can­cer tar­get — and turn­ing that dis­cov­ery in­to what be­came the block­buster Her­ceptin — has formed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

A service from the Financial Times